Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting epidermal growth factor receptor--are we missing the mark?

Janet E Dancey1, Boris Freidlin

  • 1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA.

Lancet (London, England)
|July 11, 2003
PubMed
Summary

Epidermal growth factor receptor (EGFR) inhibitors show promise in cancer therapy. Further research is needed to identify patient subgroups likely to respond to EGFR inhibitors and optimize treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changing standard of care during a randomized trial: examples, considerations and guidelines.

Journal of the National Cancer Institute·2026
Same author

Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A note on rank-preserving structural failure time models to account for crossover.

Clinical trials (London, England)·2026
Same author

The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024).

Cancers·2025
Same author

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.

Clinical trials (London, England)·2025
Same author

Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials.

JCO oncology advances·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant epidermal growth factor receptor (EGFR) signaling drives cancer proliferation, migration, invasion, and angiogenesis.
  • EGFR is a validated target for cancer therapeutics, with monoclonal antibodies and small molecules in clinical development.
  • Preclinical data suggest EGFR inhibitors impair tumor growth and synergize with standard therapies.

Purpose of the Study:

  • To review the role of EGFR in cancer and the therapeutic potential of EGFR inhibitors.
  • To discuss the clinical development of EGFR inhibitors, including gefitinib for non-small-cell lung cancer (NSCLC).
  • To identify future research directions for optimizing EGFR inhibitor therapy.

Main Methods:

  • Review of preclinical and clinical studies on EGFR inhibitors.

Related Experiment Videos

  • Analysis of gefitinib's approval and trial data in NSCLC.
  • Discussion of challenges and future research needs in EGFR-targeted therapy.

    • Main Results:

    • EGFR inhibitors are well-tolerated and demonstrate anti-tumor activity in early clinical trials.
    • Gefitinib (Iressa) was approved for advanced NSCLC patients previously treated with chemotherapy, with a ~10% response rate in refractory disease.
    • Randomized trials showed no survival benefit when gefitinib was added to chemotherapy in previously untreated NSCLC patients.

    Conclusions:

    • EGFR inhibitors represent a promising class of targeted cancer therapeutics.
    • Predictive biomarkers are crucial for selecting patients who will benefit from EGFR inhibitors.
    • Further clinical trials are needed to define optimal dosing, scheduling, and combinations for EGFR inhibitors.